Amgen · 21 hours ago
Scientific Director
Washington, DC
Full-time
Hybrid
Lead/Staff, Director/Executive
4+ years expAmgen is seeking a Scientific Director to serve as a Project Toxicologist and a Subject Matter Expert. The role involves developing nonclinical safety strategies and collaborating with project teams to advance therapeutics across various modalities.
BiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Develop and implement a fit-for-purpose nonclinical safety strategy based on a strong scientific foundation, flexibly evolve the strategy in response to team goals and emerging data and lead multidisciplinary TSRS teams
Partner with project teams developing therapeutics leveraging a variety of modalities (including biotherapeutics, small molecules and RNA therapies) to treat diseases in inflammation, oncology and/or cardiometabolic diseases, including obesity and rare diseases
Conduct scientific due diligence for business development opportunities in oncology and CMD therapeutic areas
Develop subject matter expertise related to a specific modality, therapeutic area, or safety concern
Qualification
Required
Doctorate degree in Toxicology or a related scientific field, and 4 years of experience OR
Master's degree and 7 years of experience OR
Bachelor's degree and 9 years of experience
Excellent and professional communicator; proven ability to influence a broad spectrum of partners toward achieving business goals
A proven sustained track record of scientific leadership in drug development (including IND/CTA filings) as well as in nonclinical development with a strong understanding of cross-functional needs and the ability to develop integrated plans to enable successful development of a therapeutic
Experience with matrix management and demonstrated effective mentoring skills
Presented nonclinical safety issues at national and international regulatory meetings and participate in external industry initiatives to improve drug safety assessment paradigms
Preferred
A minimum of 10 years of drug development experience, at all stages of development including late-stage assets and interactions with global regulatory agencies for IND/CTA and NDA/BLA filings
Expertise in the field of immunology, either through immune-toxicology, immune-oncology or immunology related drug-target support
End-to-end small and large molecule safety assessment experience across multiple therapeutic areas and modalities potentially including antibody drug conjugates and T-cell engagers
External visibility as a toxicology expert as demonstrated by a strong external presentation and publication record and leadership of external collaborative groups
Comfortable operating as a cross-functional and inter-functional thought partner on multi-disciplinary teams across R&D functions
Experience supporting business development efforts in the conduct of due diligence evaluations as translational safety team member
Experienced scientific leader with direct or matrixed management experience
Diplomate of the American Board of Toxicology
Benefits
A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions
Group medical, dental and vision coverage
Life and disability insurance
Flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models where possible.
Company
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
10001+ employees
H1B Sponsorship
Amgen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (429)
2024 (485)
2023 (485)
2022 (540)
2021 (460)
2020 (444)
Funding
Current Stage
Public CompanyTotal Funding
$28.5B2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO
Leadership Team
Robert Bradway
Chairman and Chief Executive Officer
Jay Bradner
Executive Vice President of R&D, and Chief Scientific Officer
Recent News
2026-01-24
2026-01-22
Company data provided by crunchbase